Phenomenex Inc, Torrance, Calif, has signed a definitive agreement to be acquired by Danaher Corp, Washington, DC. Phenomenex will continue to function as a standalone operating company, retaining the Phenomenex brand, personnel, and sites.
Developing proprietary chromatography consumables and serving the liquid and gas chromatography market, Phenomenex has a portfolio of more than 7,000 products supporting a broad diversity of applications in clinical research, drug discovery and development, environmental analysis, food safety, forensic toxicology, and petrochemistry. More than 700 employees sell and provide support for Phenomenex products, through direct and distributor channels in 92 countries.
“Phenomenex is a widely recognizable brand that we are proud to say is highly respected and well established as providing high-quality consumables to the scientific community worldwide,” says Fasha Mahjoor, CEO of Phenomenex. “Joining Danaher will allow us to maintain the high pace of innovation that our customers and international distributors have come to expect from us. This is our opportunity to further expand our research and development activities, benefit our customers with a more diversified product portfolio, and reinforce our market leadership.”
“We are thrilled to have Phenomenex join Danaher’s life sciences portfolio of businesses, which include Sciex, Beckman Coulter Life Sciences, Pall, Leica Microsystems, and Molecular Devices,” says Dan Daniel, executive vice president at Danaher. “Phenomenex is a strong business characterized by high growth rates and margins and excellent growth prospects driven by increasing analytical testing needs in the health, research, and environmental segments. The Danaher business system (DBS) has a strong track record of helping businesses rapidly scale operations and create long-term customer value. We look forward to supporting the Phenomenex team in leveraging DBS tools for growth and welcoming them to our life sciences team.”
The transaction is subject to customary closing conditions and regulatory approvals, and is expected to close in late 2016.